ijms-logo

Journal Browser

Journal Browser

New Molecular Biology and Perspective: Heart Failure

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 3059

Special Issue Editors


E-Mail Website
Guest Editor
Department of Cardiology, OLVG, 1091 AC Amsterdam, The Netherlands
Interests: heart failure; non-invasive cardiac imaging

E-Mail Website
Guest Editor
1. Institute of Physiology, Department Cellular and Translational Physiology, Ruhr University Bochum, Bochum, Germany
2. Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, Katholisches Klinikum Bochum, St. Josef-Hospital, Bochum, Germany
Interests: heart failure; molecular and experimental cardiology; cellular and translational physiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure is characterized by increasing prevalence, complex pathophysiological mechanisms and dismal clinical outcomes irrespective of left ventricular ejection fraction. Despite recent innovations in heart failure care and drug therapy, continuous improvement in mechanistic insights continues to be urgently needed in order to fuel the development of potential new treatment avenues. This Special Issue will focus on novel insights in heart failure pathophysiology and their translation to clinical medicine. In recent years, important progress has been made in unraveling signaling pathways and potential molecular targets involved in heart failure pathophysiology through the use of sophisticated experimental techniques in a variety of experimental in vitro and in vivo models and human myocardial tissue samples. Increased understanding of heart failure pathophysiology at the molecular level is expected to contribute to better comprehension and the more successful implementation of novel drug treatments for patients with heart failure.

Dr. Loek Van Heerebeek
Dr. Nazha Hamdani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • signaling
  • pathways
  • molecular
  • pathophysiology
  • proteomics
  • transcriptomics

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 2304 KiB  
Review
Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease
by Cuicui Xu, George Tsihlis, Katrina Chau, Katie Trinh, Natasha M. Rogers and Sohel M. Julovi
Int. J. Mol. Sci. 2024, 25(5), 2658; https://doi.org/10.3390/ijms25052658 - 24 Feb 2024
Viewed by 1730
Abstract
Chronic kidney disease (CKD) affects > 10% of the global adult population and significantly increases the risk of cardiovascular disease (CVD), which remains the leading cause of death in this population. The development and progression of CVD—compared to the general population—is premature and [...] Read more.
Chronic kidney disease (CKD) affects > 10% of the global adult population and significantly increases the risk of cardiovascular disease (CVD), which remains the leading cause of death in this population. The development and progression of CVD—compared to the general population—is premature and accelerated, manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. CKD and CV disease combine to cause multimorbid cardiorenal syndrome (CRS) due to contributions from shared risk factors, including systolic hypertension, diabetes mellitus, obesity, and dyslipidemia. Additional neurohormonal activation, innate immunity, and inflammation contribute to progressive cardiac and renal deterioration, reflecting the strong bidirectional interaction between these organ systems. A shared molecular pathophysiology—including inflammation, oxidative stress, senescence, and hemodynamic fluctuations characterise all types of CRS. This review highlights the evolving paradigm and recent advances in our understanding of the molecular biology of CRS, outlining the potential for disease-specific therapies and biomarker disease detection. Full article
(This article belongs to the Special Issue New Molecular Biology and Perspective: Heart Failure)
Show Figures

Figure 1

22 pages, 1117 KiB  
Review
Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device
by Antonella Galeone, Cinzia Buccoliero, Barbara Barile, Grazia Paola Nicchia, Francesco Onorati, Giovanni Battista Luciani and Giacomina Brunetti
Int. J. Mol. Sci. 2024, 25(1), 288; https://doi.org/10.3390/ijms25010288 - 24 Dec 2023
Viewed by 994
Abstract
Left ventricular assist devices (LVADs) represent the final treatment for patients with end-stage heart failure (HF) not eligible for transplantation. Although LVAD design has been further improved in the last decade, their use is associated with different complications. Specifically, inflammation, fibrosis, bleeding events, [...] Read more.
Left ventricular assist devices (LVADs) represent the final treatment for patients with end-stage heart failure (HF) not eligible for transplantation. Although LVAD design has been further improved in the last decade, their use is associated with different complications. Specifically, inflammation, fibrosis, bleeding events, right ventricular failure, and aortic valve regurgitation may occur. In addition, reverse remodeling is associated with substantial cellular and molecular changes of the failing myocardium during LVAD support with positive effects on patients’ health. All these processes also lead to the identification of biomarkers identifying LVAD patients as having an augmented risk of developing associated adverse events, thus highlighting the possibility of identifying new therapeutic targets. Additionally, it has been reported that LVAD complications could cause or exacerbate a state of malnutrition, suggesting that, with an adjustment in nutrition, the general health of these patients could be improved. Full article
(This article belongs to the Special Issue New Molecular Biology and Perspective: Heart Failure)
Show Figures

Figure 1

Back to TopTop